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Abstract
Background: Carpal tunnel syndrome (CTS) is the commonest peripheral nerve disorder in the UK, with over
52,996 carpal tunnel decompressions performed in 2011. By 2030, this figure is estimated to double. Whilst
evidence supports conservative measures for mild symptoms, and early surgery for severe symptoms, controversy
remains over the most appropriate management for patients that present with moderate disease, with regard to
early surgery or late surgery following steroid injection. Injection versus Decompression for Carpal Tunnel
Syndrome-Pilot trial (INDICATE-P) is a feasibility study for a multicentre, randomised controlled trial (INDICATE) to
determine whether patients over the age of 18 with moderate CTS should undergo early surgical decompression of
the median nerve or a single steroid injection (followed by later surgery if required).
Methods/design: INDICATE-P is a feasibility study for an open (non-blinded) randomised controlled pilot trial.
Eligible participants will be adults with a clinical diagnosis of moderate CTS. This is defined as symptoms disturbing
sleep or restricting activities of daily living or work, despite a 2-week trial of night splints. Participants will be
randomised to one of two possible interventions: surgical decompression or a single steroid injection (followed by
surgery later if required). Clinical outcome measures will be captured by postal questionnaire at 1, 3, 6 and
12 months post-randomisation. In order to improve the study design for the main INDICATE trial, feasibility data will
also be collected to identify difficulties in recruitment and retention, to gain patient feedback on questionnaires
and to confirm the suitability of the proposed outcome measures.
Discussion: The INDICATE-P feasibility study will contribute to the design and execution of the INDICATE trial,
which will seek to assess the safety and effectiveness of two approaches to treatment for patients over 18 years of
age with moderate CTS: early carpal tunnel decompression or a single steroid injection (followed by later surgery).
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Background
Carpal tunnel syndrome (CTS) is the most common
chronic hand condition referred for surgery. Incidence
of surgery for CTS is increasing worldwide [1–4]. The
UK has seen a 34% increase in the number of carpal tun-
nel decompression surgeries between 1998 and 2015,
with the number of operations in 2030 estimated to be
105,000 per year: double the number in 2011 [4].
Whilst patients with mild CTS can improve both clin-
ically and neurophysiologically [5–7], the majority of
cases eventually increase in severity over time [8].
The treatment of CTS depends on severity of symp-
toms. Severe CTS is defined as presence of thenar muscle
wasting and constant numbness. Mild CTS should be
treated non-operatively, whilst moderate CTS can be
treated either non-operatively (wrist splinting or steroid
injecting [9–12]) or with surgery [13]. There is no consen-
sus as to the clinical distinction between mild and moder-
ate CTS or how the latter should be treated [14].
Treatment
Steroid injections provide a good initial response in
around 70–90% of patients with mild and moderate
CTS, but relapse is common. The duration of effect
reported in the literature varies, but one study
showed that 63% of patients had a sustained effect
after 6 months, but only 34% after 18 months [15].
The risks of injection are small, with the incidence of
median nerve injury from intra-neural injection esti-
mated to be <0.1% in competent hands [16]. There is
no evidence to guide treatment following relapse after
steroid injection, though if the duration of effect was
reasonable, some patients prefer to have further injec-
tions and avoid surgery [12].
Carpal tunnel decompression (CTD) is 90–95% effect-
ive in permanently relieving pain, paraesthesia and inter-
mittent numbness in CTS [17, 18]. However, it involves
higher risk and longer recovery time for the patient than
steroid injection. A survey of 4000 patients who received
CTD found that 2 years after surgery, only 75% consid-
ered the operation a success and 8% were worse off [19].
This study shows a clear trend to improved results in
patients with moderate CTS compared to mild and se-
vere CTS.
There is variability in Clinical Commissioning Group
(CCG) policies and clinician approaches: this stems from
the paucity of good evidence. Only two randomised con-
trolled trials have compared steroid injections to surgery.
Ly-Pen et al. [18], across 163 wrists, found no significant
difference 2 years, but no validated symptom score was
used, and they found high cross-over between treatment
groups. Hui conducted a trial of 50 patients, finding that
surgery provided greater relief of symptoms at 20 weeks
[20]. A 2008 Cochrane review [21] suggests that it is un-
clear whether surgery is superior to steroid injection.
For patients with moderate CTS, the dilemma of
whether to opt for surgery or steroid injection remains.
The INDICATE study will seek to assess the clinical and
cost effectiveness of the two approaches to treatment;
early surgery or a single steroid injection (with later sur-
gery if required).
Methods/design
Injection versus Decompression for Carpal Tunnel
Syndrome-Pilot trial (INDICATE-P) is a pilot study to
inform the design of the multicentre, randomised con-
trolled INDICATE study, specifically in terms of feasibil-
ity of recruitment and data collection. The aim of the
main trial is to assess whether early surgery or a single
steroid injection (with later surgery if required) is the
better treatment approach for patients with moderate
CTS. The objectives of this feasibility study are as
follows:
Primary objective
To assess the feasibility of conducting the INDICATE
trial with regards to recruitment, data collection and
outcome measurement. In order to achieve this, a range
of study process measures and clinical and patient-
reported outcomes will be collected as listed below.
Secondary objectives
1. Identify challenges and differences associated with
recruiting from the primary and secondary care
2. Assess patient views on the follow-up method and
data collection




1. Number of potentially eligible patients identified in
secondary and primary care units
2. Number of patients approached to take part in the
study
3. Proportion of patients who consented to take part in
the study (out of those approached)
4. Proportion of patients who received the allocated
treatment and reasons for any non-compliance (out
of those randomised)
5. Proportion of patients with a valid response at each
follow-up time point (out of those randomised)
6. Assessing the process of establishing primary care
recruitment portals, and the proportion of patients
recruited via this process.
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Baseline and follow-up questionnaires will contain a
variety of patient-reported clinical outcomes that are
candidates for use in the main INDICATE trial. The fol-
lowing will be collected from participants in both trial
arms for comparison:
 Symptoms and function will be measured using
Boston Carpal Tunnel Assessment Questionnaire
[22]; this is a validated patient-orientated scale spe-
cific for CTS. It has two parts: a symptom severity
scale (SSS) consisting of 11 questions and a function
status scale (FSS) with 8 questions. Each question is
scored from 1 to 5, and the mean is calculated for
each subscale. The change in SSS score will consti-
tute the primary outcome for the main trial (baseline
1, 3, 6 and 12 months).
 Pain will be measured using the palmar pain scale
[23]; this is a validated scale for pain-related activity
limitation (baseline 1, 3, 6 and 12 months).
 Patient satisfaction [24] will be assessed using a
variation of the Oxford Satisfaction Index. This
involves transition questions developed and utilised
recently by members of the study team to measure
patients’ satisfaction post treatment. (12 months)
 Information on time off work/activities (1, 3, 6 and
12 months)
 Standardised health outcomes will be measured using
EuroQol-5D-3L (baseline 1, 3, 6 and 12 months)
Additionally we will also collect:
 details of other healthcare received related to the
patient’s CTS
 complication data
 patient preference regarding postal or online
questionnaires as part of study follow-up
 patient views on the study questionnaires and trial
participations
Clinical outcomes:
These are collected via the patient-reported question-
naires and the case report forms completed for the
study interventions. Information collected includes:
 Details on any complications (whether surgical or not)
 Details on the procedure time, local anaesthetic
used, antibiotics prescribed, operative findings, staff
involved in the procedures and planned follow-up
regimen are collected on the injection and surgery
case report form (CRF) at the time of surgery.
Adverse events
Adverse events (AE) will be captured primarily through
patient-reported forms, but also by clinicians (either at
participating centres or in primary care). AE’s will be re-
ported by participating centres.
Expected adverse events
The following is a list of events that are deemed “ex-
pected” in relation to these treatment approaches for
moderate carpal tunnel syndrome:
 Surgical site infection—as defined using the Centre
of Disease Control and Prevention Criteria
 Nerve injury—for either intervention, defined as
permanently reduced median nerve sensibility or
motor power
 Vessel injury—defined as a superficial palmar arch
injury seen intra-operatively or a haematoma requiring
drainage
 Complex regional pain syndrome (CRPS)—defined
using the Budapest Criteria
Recruitment
Participants will be recruited prospectively at the partici-
pating sites. The process of patient identification and re-
cruitment will depend on the local treatment pathways
at each participating site: from secondary care (Glouces-
ter, Canterbury and Plymouth, UK) or from primary care
using Patient Identification Centres at local General
Practices (Gloucestershire, UK). Practices will identify
patients by searching their databases on a monthly basis
for patients with a new diagnosis of CTS. These patients
will be sent a patient information sheet and a letter in-
viting them to contact the local research team in sec-
ondary care if they are interested in participating in the
trial. The flowchart in Fig. 1 details the recruitment
process.
Informed consent
The patient must personally sign and date the latest ap-
proved version of the informed consent form before any
study-specific procedures are performed.
Consent will be obtained before any study procedures
are performed, including any required nerve conduction
studies.
If an eligible patient does not wish to participate, pa-
tients will be asked if they would be willing to provide a
reason for this. Patients are under no obligation to do
so, but information like this will be utilised to inform
the definitive trial.
With patient consent, GPs will be notified of their pa-
tient’s participation in the trial.
Number of participants
A sample size of 40 patients will be used for this feasibil-
ity study. As this is a feasibility study, the study is not
powered for pre-defined statistical tests. Instead, 40
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participants are anticipated to be sufficient to enable a
robust assessment of the objectives, i.e. the feasibility of
a larger definitive trial, and also to provide a sufficiently
robust estimate to inform a sample size calculation for
the definitive trial.
Study population
Patients over 18 years of age, who have moderate car-
pal tunnel syndrome, will be considered eligible for
inclusion in this study. This includes patients who
have tried night splints for at least 2 weeks, have dis-
turbed sleep or have limited ability to perform activ-
ities of daily living (including work-related tasks).
Nerve conduction studies will be conducted to pro-
vide an objective measure of electrophysiological se-
verity and to allow analysis of their effectiveness as a
prognostic indicator. Patients must be able to consent
for themselves, have an understanding of the nature
of the study and be willing to complete the follow-up
requirements.
Inclusion criteria
 All three of the following must be present:
O Intermittent paraesthesia predominantly within,
but not exclusive to, the median nerve distribution
O Nocturnal hypoaesthesia, dysaesthesia or
paraesthesia (including on waking)
O A positive provocation test (e.g. Tinel’s, Phalen’s,
Durkan’s pressure or hand elevation test)
 Symptoms present for at least 3 months
 Patients’ symptoms must either:
O disturb their sleep or
O limit their ability to perform work or activities
of daily living
 Patients must have failed a trial of night splints for
at least 2 weeks
 Age >18 years
Exclusion criteria
The participant may not enter the study if ANY of the
following apply:
Fig. 1 Patient recruitment flowchart
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 Severe CTS
○ thenar muscle wasting or
○ continuously reduced light touch sensation in
median nerve distribution (compared to opposite
unaffected side or unaffected finger)
 Previous carpal tunnel surgery or steroid injection
(either side)
 CTS secondary to:




 Clinical or neurophysiological evidence of
generalised or other peripheral neuropathy (e.g.
ulnar nerve) or cervical radiculopathy (not based on
NCS only performed for the purposes of the trial).
 Other symptomatic disorder in the affected hand
diagnosed in the last 6 months or requiring
treatment
 Patients in whom the baseline questionnaire cannot
be completed due to cognitive difficulties
Patients with bilateral symptoms will have only one
hand involved in the trial. This will be the hand with the
more severe symptoms. The lesser-affected hand can be
treated either by surgery or injection as the patient
chooses, but treatment must take place after the treat-
ment for the more severely affected hand.
Interventions
Eligible and consenting patients will be randomised to
receive one of the two possible treatment approaches:
Surgery
Surgeons treating INDICATE-P patients will regularly
perform carpal tunnel decompression and will use the
technique with which they are most familiar, whether it
is open or endoscopic surgery, to avoid any learning
curve effect.
Peri-operative management including anaesthesia,
analgesia and dressings should follow local protocols.
Post-operative management including dressing changes,
advice, exercises, scar management and follow-up ap-
pointments should follow local protocols or the sur-
geon’s preference. Specifically, it will not be necessary to
have a follow-up appointment in secondary care, if that
is not usual local practice.
The designated investigator at the centre providing the
surgery should ensure that the operative data is recorded
on the appropriate CRF. The purpose of this form is to
collect data on the type of surgery performed and key
costs.
Steroid injection
All participants allocated to receive a steroid injection
will receive the standard injection offered at their site.
The technique of the injection will not be standardised,
but the practitioner should regularly give injections for
CTS and should use the technique with which they are
most familiar. Details of this, along with the steroid and
its dosage, will be recorded on the injection form.
Further injections are not advisable whilst the patient
is in the study, however, if more than one injection is
given, this needs to be recorded as further treatment on
the complication form.
If symptoms recur following either the injection or
surgery, participants should contact the local research
team by email or by phone. Patients will then be referred
to the centre of their choice to discuss further treatment
options. This may include surgery as described above.
Data about any surgery following injection will also be
recorded on the appropriate CRF.
Randomisation
A web-based randomisation system will be provided by
the Oxford Clinical Trials Research Unit (OCTRU). The
trial statistician will generate the random sequence,
which will be simple block (with varying block size) ran-
domisation, stratified by centre to ensure a similar num-
ber of patients are allocated to each treatment arm at
each site. The research nurse will randomise participants
once they have given informed consent and attended
their baseline assessment. The randomisation system will
automatically forward to the central study office in
Oxford, and this will be sent to the nominated people at
each site. The randomised treatment will be recorded on
the site’s randomisation log. This log will be maintained
by the local study team at each site.
Once a patient has been randomised, a copy of the pa-
tient’s consent form and the patient details form will be
forwarded to the central study office in Oxford to facili-
tate the postal follow-up.
Data collection
Patient demographics will be recorded on the patient de-
tails form. Data recorded will include date of birth, gen-
der, hospital number, and the hand involved in the
study.
Baseline data collected will include information about
the patient’s pain and function, questions about their
general health, duration of symptoms and employment
status.
Neurophysiological testing (nerve conduction studies)
are required as a baseline assessment. Results from these
will be assessed by local staff using a standardised severity
scale, anonymised and sent to Dr Jeremy Bland (co-inves-
tigator and neurophysiologist) at East Kent University
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Hospitals NHS Foundation Trust. He will assess the NCS
reports and apply a severity grade to them according to
the Bland Criteria [25].
If the research clinic is held in a hospital with a neuro-
physiology department, then ideally the nerve conduc-
tion studies will be scheduled at the same time as the
baseline appointment to minimise inconvenience to the
patient. If the research clinic is held in a hospital that
does not have a neurophysiology department then the
nerve conduction studies will need to be performed be-
fore the patient can be randomised. Specific consent for
the studies will be given before they are performed. The
patient may not need to return for another appointment,
as the research team could proceed with randomisation
and liaise with the patient via telephone about their ran-
domised treatment and any further appointments that
may be required. Extra appointments will be avoided
where possible. A member of the research team will tele-
phone the patient just prior to randomising to re-
confirm that the patient still consents to take part.
Follow-up assessments
Clinical outcome measure time points will be at baseline
and 1, 3, 6, and 12 months post-randomisation.
Follow-up for study purposes will be completed via
post. Clinical follow-up will occur as per routine practice
at each participating centre.
Blinding
INDICATE-P will be an open study where those deliver-
ing the care will not be blinded to the intervention nor
will the patient who has received it or the outcome
assessors.
Analysis
A single analysis of data will take place once the study has
ceased recruiting, and the last patient has reached their
final assessment. No interim analysis is planned. Given
this is a feasibility study, no formal statistical analysis of
the data between groups is planned, i.e. no statistical tests
for statistically significant differences in outcomes be-
tween trial arms will be performed. Descriptive analyses of
outcome data will be carried out using appropriate sum-
mary measures (e.g. number of events and percentage for
binary measures). Measures will be quantified, and where
appropriate an associated 95% confidence interval calcu-
lated (e.g. using the Wilson score interval method (or an
equivalent one) for binary measures). No imputation of
missing data will be carried out.
Patient recruitment data
The number of patients recruited per month will be pre-
sented by centre and overall. Reasons for ineligibility
and non-participation where eligible will be summarised.
The different centres participating in this pilot study
represent different referral pathways that will aid in
assessing the feasibility of each recruitment approach.
Analysis of compliance
The compliance with the randomised intervention will be
summarised as a proportion both overall and by treatment
arm, together with reasons for non-compliance and with-
drawals, where available. The time between randomisation
and the trial intervention will also be summarised.
Completeness of data returns will be summarised by
follow-up time point.
Analysis of clinical and patient-reported outcomes
Outcome data will be summarised overall and according
to the allocated intervention irrespective of the actual
treatment received at baseline and during the follow-up
time period. Results of nerve conduction studies will
also be collected and categorised according to the Bland
criteria [25].
Complications reported during the trial follow-up will
also be summarised by allocated intervention.
Discussion
CTS is the commonest peripheral nerve disorder in the
UK and is increasing in incidence in the population,
representing a significant disease burden. A lack of
strong evidence regarding treatment has resulted in sig-
nificant variability between both regions and individual
clinicians, across a range of specialties.
INDICATE-P will inform design and methodology of
the main INDICATE trial. The aim of the pilot study is
to assess feasibility of recruitment and data collection, in
particular, the number of eligible patients that present
over the time period, the number who consent to par-
ticipate, the number who receive the allocated treatment
and complete follow-up, and also reasons for non-
compliance. This information will aid in the practical de-
velopment and application of INDICATE; a large, multi-
centre RCT that aims to determine whether steroid
injection (with late surgery) or early surgery provides the
best outcome for patients with moderate CTS.
Trial status
The trial is currently recruiting.
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